Merchionne Francesca, Quintana Giovanni, Gaudio Francesco, Minoia Carla, Specchia Giorgina, Guarini Attilio, Quarta Giovanni, Pavone Vincenzo, Melpignano Angela
Hematology and Bone Marrow Transplantation Unit, Antonio Perrino Hospital, Brindisi, Italy.
Hematology and Bone Marrow Transplantation Unit, Antonio Perrino Hospital, Brindisi, Italy.
Leuk Res. 2014 Dec;38(12):1446-50. doi: 10.1016/j.leukres.2014.10.001. Epub 2014 Oct 22.
For patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who are not eligible for intensive chemotherapy because of comorbidities, advanced age, or relapse after heavy salvage regimens, treatment options are very limited and prognosis is poor. We retrospectively analyzed 29 patients with relapsed/refractory DLBCL treated with combination bendamustine plus rituximab (BR) between July 2010 and January 2014 to evaluate overall response rate (ORR), progression-free survival (PFS), duration of response (DOR) and treatment safety. Twenty-eight patients were available for this analysis. ORR was 50% (14 patients), with 39.3% CR (11 patients), and 10.7% PR (3 patients). SD was reported in 2 patients (7.2%) and PD in 12 patients (42.8%). At the median follow up of 8 months (range 1-37.4 months), the median PFS was 8 months for all patients (95% CI 5.5-26.6). The median DOR was 24.7 months (95% CI 3.2-24.7). Grade 3/4 toxicity observed included hematologic events: lymphopenia (42.8%), neutropenia (32.1%), anemia (17.2%), and thrombocytopenia (14.2%). BR can be considered to have a role in the treatment of patients with relapsed/refractory DLBCL with limited therapeutic options, in that it can induce long-term remission in some patients with an acceptable toxicity profile.
对于因合并症、高龄或在强烈挽救方案后复发而不适合接受强化化疗的复发或难治性弥漫性大B细胞淋巴瘤（DLBCL）患者，治疗选择非常有限且预后较差。我们回顾性分析了2010年7月至2014年1月期间接受苯达莫司汀联合利妥昔单抗（BR）治疗的29例复发/难治性DLBCL患者，以评估总缓解率（ORR）、无进展生存期（PFS）、缓解持续时间（DOR）和治疗安全性。28例患者可用于此次分析。ORR为50%（14例患者），完全缓解（CR）率为39.3%（11例患者），部分缓解（PR）率为10.7%（3例患者）。2例患者（7.2%）病情稳定（SD），12例患者（42.8%）疾病进展（PD）。在中位随访8个月（范围1 - 37.4个月）时，所有患者的中位PFS为8个月（95%置信区间5.5 - 26.6）。中位DOR为24.7个月（95%置信区间3.2 - 24.7）。观察到的3/4级毒性包括血液学事件：淋巴细胞减少（42.8%）、中性粒细胞减少（32.1%）、贫血（17.2%）和血小板减少（14.2%）。对于治疗选择有限的复发/难治性DLBCL患者，BR可被认为在治疗中发挥作用，因为它可以在一些患者中诱导长期缓解，且毒性可接受。
